Drug Therapy: 1. &-Adenosyi-L-Meothionine (SAM) has been shown to improve estrogen-induced liver cholestasis and stone formation in mice. In humans, SAMe acts on estrogen metabolites through methylation, stimulates membrane phospholipid synthesis, and prevents estrogen-induced cholestasis by increasing the phospholipid content of liver plasma. In 1984, Freeza used 800 mg/d intravenously to reduce pruritus, significantly decrease SALT and bilirubin, and significantly decrease serum bile acids, with a relapse about 1 day after discontinuation of the drug, which was not achieved with SAMe 200 mg/d intravenously. In 1988, Freez et al. also reported that SAMe could protect the liver and normalize the cholesterol index in estrogen-sensitive patients in a voluntary human trial, and therefore SAMe is a physiological antidote. In 1990, Masia et al. used SAMe 800 mg/d intravenously for 16 days as a course of treatment, which not only reduced itching and improved liver function but also reduced the rate of preterm delivery, which he considered a safe and effective drug of choice for ICP. 2, Ursodeoxycholic acid. The mechanism of action of ursodeoxycholic acid (UDCA), also known as ursodeoxycholic acid, is not clear, but may be to change the composition of the bile acid pool, replace the endogenous bile acids that are highly cytotoxic to the hepatocyte membrane sheet with flowing water, and inhibit the intestinal reabsorption of sulfuric bile acids and reduce the blood bile acid level to improve the fetal environment. 1992 Palma on The first group of 5 ICP received UDCAIg orally daily for 20 days and the other 3 in the second group received 1g daily with an interruption of 14 days after 20 days. The latter group showed significant improvement in pruritus and liver function during the treatment period, which was repeated after stopping the drug, but improved again in the second course. 3, dexamethasone, dexamethasone (dexamethazone) can inhibit the secretion of fetal adrenal dehydroepiandrosterone through the placenta, reduce estrogen up into to reduce cholestasis, dexamethasone can also promote the maturation of fetal lung, in order to avoid the occurrence of neonatal respiratory distress syndrome, 1992 Hirvioja report on 10 cases of 28 to 32 weeks of gestation ICP; daily In 1992, Hirvioja reported that in 10 cases of ICP at 28 to 32 weeks of gestation; 12 mg of dexamethasone was given orally daily for 7 days, and the dose was reduced to total discontinuation in the last 3 days, resulting in a reduction or disappearance of pruritus in all patients. Total bile acids were significantly reduced, so it can be used as a drug for the treatment of ICP. 4.Anti-cholestatic amine. It is a strong alkaline ion exchange resin that combines with bile acids in the intestinal lumen to form a complex that is absorbed by humans, thus preventing bile acids from repeatedly entering the hepatic-intestinal circulation and reducing the serum leg acid level. There was a decrease and small change in CA level, and the symptoms recurred after stopping the drug. 5. Phenobarbital. Phenobarbital is an enzyme inducer, which increases the ability of glucuronide binding and the function of liver to eliminate bilirubin, causing a decrease in bilirubin, at the same time, it can also increase the rate of bile acid secretion from bile ducts, and by changing the activity of cholesterol-7a a hydrolase to shadow bile production. ICP patients; 6, cases had varying degrees of reduction in pruritus, SGPT was mildly decreased, but blood CA and CDCA levels were not changed much, Heikkinen suggested that it may be the sedative effect of nerve through and reduce pruritus symptoms.